Expected Moves

Givaudan's scheduled Q3 2026 sales update will reveal whether recent pricing actions can offset deteriorating margins. Given the current $77.67 price testing the 200-day SMA ($77.68), an upward resolution targets $84.05, while sustained margin erosion risks a drop to the $70.78 DCF valuation.

Assuming the stock retraces to its $70.78 fundamental value, market focus will shift to a likely mid-quarter strategy update on 2027 pricing power. A successful structural cost-reduction plan targets $76.00, but capitulation on pricing power breaks the 52-week low toward $76.00.

The mandatory full-year earnings print will provide a definitive look at FY26 net income and cash flow realization. Launching from a depressed $64.00 level, a restorative guidance targets $70.50, whereas missing the reset bar risks a deeper structural derating to $58.00.

A seasonal update on Q1 sales volumes. Originating from $70.50, confirmation of stabilized input costs and volume recovery targets $76.50, whereas renewed supply chain friction or sluggish demand sends shares back to $64.50.